Benzinga's Volume Movers

Imprivata Inc IMPR surged 31.21 percent to $19.02. The volume of Imprivata shares traded was 8485 percent higher than normal. Imprivata reached a definitive deal to be bought by an affiliate of Thoma Bravo, LLC, a private equity firm, for $544 million.
Juno Therapeutics Inc JUNO shares moved up 16.7 percent to $32.44. The volume of Juno Therapeutics traded was 1061 percent higher than normal. Juno Therapeutics reported that that U.S. Food and Drug Administration removed a clinical hold on the Phase II clinical trial of JCAR015, also known as the "ROCKET" trial.
Level 3 Communications, Inc. LVLT shares climbed 3.5 percent to $56.26. The volume of Level 3 Communications shares traded was 443 percent higher than normal. Industry source told Benzinga that Level 3 is reviewing strategic alternatives to maximize holder value, including outright sale or large buyback.
ADTRAN, Inc. ADTN shares rose 3.6 percent to $20.4601. The volume of ADTRAN shares traded was 432 percent higher than normal. ADTRAN reported better-than-expected Q2 earnings, but the company lowered its guidance.